

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau



EP 0091958

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification³ : A61K 39/44; B01J 13/02 C07G 7/00; G01N 33/48, 33/54 G01N 33/80	A1	(11) International Publication Number: WO 83/01571 (43) International Publication Date: 11 May 1983 (11.05.83)
(21) International Application Number: PCT/US82/01524 (22) International Filing Date: 28 October 1982 (28.10.82) (31) Priority Application Number: 316,126 (32) Priority Date: 29 October 1981 (29.10.81) (33) Priority Country: US (71) Applicant: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA [US/US]; 2200 University Avenue, Berkeley, CA 94720 (US). (72) Inventors: PAPAHAJOPOULOS, Demetrious, P. : 3170 Condit Road, Lafayette, CA 94549 (US). HEATH, Timothy, D. : 480 Warren Drive, No. 307, San Francisco, CA 94131 (US). (74) Agents: SIEBERT, J., Suzanne et al.; 463 Pacific Avenue, San Francisco, CA 94133 (US).		(81) Designated States: AT (European patent), BE (European patent), CH (European patent), DE (European patent), FR (European patent), GB (European patent), JP, LU (European patent), NL (European patent), SE (European patent). Published <i>With international search report.</i>

(54) Title: LIPOSOME CONJUGATES AND DIAGNOSTIC METHODS THEREWITH

(57) Abstract

A number of naturally occurring antibodies to human erythrocyte surface antigens are capable of combining with their specific antigens (for example, Rhesus factor), but are not capable of producing visible hemagglutination. Also, the sensitivity of many diagnostic methods, such as in human blood typing, depends upon cell agglutination. The present invention provides liposome-protein conjugates, especially useful for hemagglutination assays, having an enhanced agglutination capacity with respect to antibody from which the conjugates are derived.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	LI	Liechtenstein
AU	Australia	LK	Sri Lanka
BE	Belgium	LU	Luxembourg
BR	Brazil	MC	Monaco
CF	Central African Republic	MG	Madagascar
CG	Congo	MR	Mauritania
CH	Switzerland	MW	Malawi
CM	Cameroon	NL	Netherlands
DE	Germany, Federal Republic of	NO	Norway
DK	Denmark	RO	Romania
FI	Finland	SE	Sweden
FR	France	SN	Senegal
GA	Gabon	SU	Soviet Union
GB	United Kingdom	TD	Chad
HU	Hungary	TG	Togo
JP	Japan	US	United States of America
KP	Democratic People's Republic of Korea		

- 1 -

Description
Liposome Conjugates and Diagnostic
Methods Therewith

Field of the Invention

5 The present invention relates generally to liposome conjugates, and more particularly to liposome-protein conjugates which have an enhanced agglutination ability, can rapidly and sensitively agglutinate cells such as erythrocytes, lymphocytes, and leukocytes, and
10 which are useful in applications such as blood typing.

 This is a continuation-in-part of U.S. Patent Application Serial No. 129,654, filed March 12, 1980.

Background of the Invention

15 Liposomes are now well recognized as useful for delivery of therapeutic agents, such as cytotoxic drugs or other macromolecules capable of modifying cell behavior, to in vivo sites. For example, U.S. Patent 3,993,754, inventors Rahman, et al, issued November 23, 1976, discloses an improved method for chemotherapy of
20 malignant tumors in which an antitumor drug is encapsulated within liposomes and the liposomes containing the encapsulated drug are injected into an animal or man.

 It has been suggested that target, or in vivo site, specificity might be conferred on liposomes by
25 their association with specific antibodies or lectins. Methods of associating antibodies with liposomes have been described, and may be generally divided into two groups--nonspecific association and covalent attachment.

30 Nonspecific association appears to rely upon the affinity of the Fc portion of the antibody for the hydrophobic region of the lipid bilayer. However, non-

BUREAU

- 2 -

specific association appears incapable of associating more than about 15-30 microgram per micromole of lipid. Also, nonspecific association has little practical value because the liposomes are rendered more permeable than
5 their encapsulated contents and protein aggregation is produced during formation of the nonspecifically associated liposome-protein.

Prior to preparation of the covalently attached protein of coupled-protein species described in U.S. Patent Application Serial No. 129,654, attempts to
10 covalently attach protein to liposomes had been unsatisfactory. For example, some of the prior attempts had involved modifications of the proteins which tended to denature the protein, and thus a substantial loss of
15 biological activity had ensued. Other attempts to covalently attach protein to liposomes had produced very small amounts of specific attachment.

By contrast, activated liposomes in accordance with U.S. Patent Application Serial No. 129,654 are
20 readily and efficiently covalently bound to a variety of biologically active proteins with at least about 40 micrograms of protein per micromole of lipid. For example, use of the activated liposomes has achieved coupling of up to about 200 micrograms of F(ab')₂ per
25 micromole of lipid; further, such coupled liposome-protein species were shown to have an improved hemagglutinating titre by comparison to the original, soluble antibody from which they were derived.

Very recently, another efficient method for
30 coupling protein to liposomes has reported coupling of up to 600 micrograms of Fab' per micromole of phospholipid via a disulfide interchange reaction. Martin, et al., Biochemistry, 20, pages 4429-4238 (July, 1981).

- 3 -

Meanwhile, agglutination methods are known and useful for applications such as blood typing. However, many such methods have had to be performed indirectly, or have been of relatively low sensitivity. For example, the Coombs test is an indirect agglutination method in the sense that a secondary, or intermediate, antibody must be used. Further, detection of antibodies which do not produce positive agglutination (e.g., visible agglutination) when combined with their specific antigens has presented difficulties in applications such as blood crossmatching. Such serologically "incomplete" antibodies are believed to be fully functional bivalent IgG molecules, but they are unable to bridge two cells and hence do not produce positive agglutination.

15 Summary of the Invention

Accordingly, it is an object of the present invention to provide a hemagglutination reagent having an improved capacity to agglutinate erythrocytes.

20 It is a further object of the present invention to provide an agglutination method, useful for assaying erythrocyte antigens, which is rapid and sensitive.

It is yet a further object that human erythrocyte surface antigens, which are not normally capable of producing visible hemagglutination, may be agglutinated and the clumps subject to detection.

25 In one aspect of the present invention, an agglutination method useful for assaying cell surface antigens comprises providing a quantity of liposome-protein conjugates where the protein thereof supplies an antigen binding capacity for at least a majority of the liposome-protein conjugates, contacting the liposome-protein conjugates with substantially unagglutinated

30

EUREKA

- 4 -

cells to form a mixture, and examining the mixture for cell agglutination. The liposome-protein conjugates have at least about 40 micrograms of protein per micromole of lipid.

5 In another aspect of the present invention, a reagent, useful for hemagglutination, comprises liposome-protein conjugates having an antibody covalently bound to the liposomes and an antigen binding capacity for erythrocytes bearing a surface antigen for
10 which the antibody is specific. The reagent has a hemagglutinating activity which is improved with respect to the hemagglutination activity of the original antibody from which the liposome-protein conjugates are derived.

The liposome-protein conjugates and method of
15 the present invention provide considerably improved sensitivity for agglutination assays. For example, agglutination of erythrocytes by use of the liposome-protein conjugates can occur in seconds with large, clearly visible agglutinated clumps of cells. By
20 contrast, agglutination assays using the original, soluble antibody typically require minutes to produce agglutination visible to the naked eye, and the clumps of cells are much smaller. Thus, the ability of liposome-protein conjugates in accordance with the present
25 invention to produce larger, more visible clots suggests the possibility of simple, visual spot tests which need not require special optical equipment for observation, and for use in a variety of diagnostic applications.

Detailed Description of the Preferred Embodiments

30 Broadly, one aspect of the present invention is a diagnostic method wherein liposome-ligand conjugates are contacted with ligand-binding molecules to form a

EURE

- 5 -

mixture, and the mixture is examined for combinations, or interactions, between the liposome-ligand conjugates and the ligand-binding molecules. The ligand-binding molecules are carried by at least one surface, more preferably carried by a plurality of surfaces defined by discrete particles, and most preferably carried by cell surfaces. The ligand of the liposome-ligand species is in an amount of at least about 40 micrograms per micromole of lipid, and preferably is a protein having an antigen binding capacity. For example, when the protein is an antibody and the ligand-binding molecules are antigens carried by cell surfaces, then the mixture examination following the contacting step typically includes determining cell agglutination mediated by combinations between the coupled antibody and immunological partners, or specific antigens, carried on the cells. Where the ligand is protein, the conjugates will hereinafter sometimes be referred to as liposome-protein conjugates.

The at least one surface carrying the ligand-binding molecules may be a natural multivalent antigen or may also be formed by inanimate, synthetic materials. For example, among suitable non-cellular materials are polyacrylamide beads about 5-10 microns in diameter having immobilized, or covalently bound, immunoglobulin on the bead surfaces, which are commercially available from Bio-Rad Laboratories under the trademark "Immuno-bead", and polystyrene spheres about 1 micron in diameter, which may be coupled along their surfaces with immunoglobulin such as IgG, commercially available from Covalent Technology Corporation under the trademark "Covaspheres".

As used herein, ligand and ligand-binding molecules mean moieties which can interact specifically

BUREAU

- 6 -

but non-covalently with each other. One type of such moiety pairings is an antigen-antibody interaction, another is a hormone-receptor interaction, and yet another is a carbohydrate-lectin interaction.

5 Liposome-protein conjugates useful in accordance with the present invention may be prepared in various ways. For example, one suitable preparation is via activated liposome precursors where the precursor liposomes, before being covalently bound, are activated
10 by means of an oxidizing reagent. A modification of this preparation is wherein the lipid, such as gangliosides, is first oxidized and then formed into the precursor liposomes. Another suitable preparation is via disulfide bonds, as described by Martin et al, supra.

15 In any event, it is necessary that the protein be then covalently bound to the liposomes precursors in an amount of at least about 40 micrograms per micromole of lipid. A suitable preparation and properties of liposome-protein conjugates will now be more fully
20 described.

Preparation of Liposome-Protein Conjugates Via
Activated Liposome Precursors

Activated liposomes may be prepared from starting vesicles which are generally characterized
25 either as unilamellar vesicles or multilamellar vesicles. Either liposomal structure is suitable. A particularly preferred preparation is by the reverse-phase evaporation vesicle (REV) method, which is disclosed by U.S. Patent 4,235,871, and as is described in Proc. Natl. Acad. Sci.
30 U.S.A., Volume 75, No. 9, pp. 4194-4198 (1978), entitled "Procedure For Preparation of Liposomes With Large Internal Aqueous Space and High Capture by Reverse-Phase

BUREAU
CHIEF

- 7 -

Evaporation," Szoka, Jr. and Papahadjopoulos, which disclosures are incorporated herein by reference.

As is known to the art, a wide variety of materials may be encapsulated, if desired, by the precursor liposomes. For example, the precursor liposomes can encapsulate cytotoxic drugs, can encapsulate nucleic acids, and can encapsulate various proteins.

In any event, the precursor liposomes suitable for the present invention may be formed from either phosphatidylglycerol (hereinafter also referred to as "PG"), which has an oxidisable group at the polar head region, as the sole lipid, or may be formed from a mixture of two or more different lipids.

When formed from two or more different lipids, at least one of the lipids contains oxidisable groups, such as vicinal amino or vicinal hydroxyl groups, along the polar head region of the lipid molecule. For example, in the instance of vicinal amino groups, a glycolipid having galactosamine or glucosamine residue is a suitable oxidizable lipid. More usually, at least one of the lipids will have vicinal hydroxyl groups at the polar head region. Particularly preferred as one of the lipids (that is, the oxidisable lipid) in a lipid mixture are the glycolipids such as lactosyl ceramide, galactocerebroside, gangliosides, and trihexosyl ceramide, and the phospholipids, such as phosphatidylglycerol and phosphatidylinositol.

The amount of such lipids having oxidisable groups (generally herein referred to as "oxidisable lipids") may vary with respect to the total lipids forming the precursor liposomes; however, it is preferred that the mole percent of oxidisable lipids be in an amount of

BUREAU

- 8 -

at least about 10 mole percent with respect to a total of the mixture of lipids.

Particularly preferred amounts of oxidisable lipids with respect to the total lipids are illustrated by Table I, below.

TABLE I

<u>Oxidisable Lipid</u>	<u>Mole of Oxidisable Lipid To Total Lipid</u>
10 <u>Mixture</u>	
Lactosylceramide	About 10
Trihexosylceramide	About 10
Galactocerebroside	About 20
Phosphatidylglycerol	About 33-40
15 Phosphatidylinositol	About 20
Gangliosides	About 10

The structures of the preferred oxidisable lipids are well known; however, for clarity Figure 1, below, illustrates PG as representative of the general structures of the oxidisable lipids having the polar head regions and the region of non-polar tails.

BUREAU

- 9 -


Figure I: PG

Figure 1 is generally representative of all of the lipids which may be mixed to form the precursor liposomes in defining the polar head region and the non-polar tails. The Figure 1 structure is more particularly generally representative of the oxidisable lipids which have vicinal hydroxyl groups at the polar head region thereof.

As is known, the above discussed mixtures of 10 lipid molecules form precursor liposomes with the lipid molecules being arranged in either one bimolecular layer (unilamellar) or a plurality of bimolecular layer forms

BUREAU

- 10 -

an outer surface for the liposome. In an aqueous solution, the polar head regions of the lipid molecules are exposed, or extend into, the aqueous system in a generally radially outward orientation with respect to the outer surface. The non-polar tails extend radially inwardly with respect to the outer surface and form a substantially continuous hydrocarbon phase of the bimolecular layer. This substantially continuous hydrocarbon phase is relatively impermeable, and acts to encapsulate the materials inside the precursor liposomes.

Nevertheless, some mixtures of lipids forming the precursor liposomes may tend to be permeable to small molecules, and cholesterol is a desirable addition to some of these lipid mixtures for reducing the permeability of the precursor liposomes. The cholesterol tends to orientate within the bimolecular layer. Other components may be utilized in place of cholesterol to reduce the liposome permeability. For example, a phosphatidylcholine having the fatty acid saturated aliphatic chain, or non-polar tails, of a length of 18 (rather than the usual unsaturated 16 to 18 carbon chain obtainable from egg yolks) may be utilized. However, when sphingomyelin is mixed with the oxidisable lipid, the precursor liposomes thereof are inherently quite impermeable to small molecules.

A solution of precursor liposomes may thus be provided as has been described above. This solution is preferably a polar solution, such as an aqueous solution, but may also be a non-polar solution. The precursor liposomes are contacted with a sufficient amount of a relatively mild oxidizing reagent to produce activated liposomes. Where the lipids to be used for liposomes are in a non-polar solution, the oxidizing reagent may be lead

BURE.


- 11 -

tetraacetate. In the preferred polar solution, the oxidizing reagent of the contacting step is a periodate reagent, usually sodium periodate, which cleaves the vicinal amino or hydroxyl groups at the polar head regions 5 of the oxidisable lipids.



Where the solution is polar and the oxidizing agent is a periodate reagent, the pH and osmolarity of the liposome solution and an added amount of periodate reagent should be substantially the same. The pH is 10 typically about 6.0 to about 8.5. The oxidizing reagent produces activated liposomes by oxidizing the oxidisable groups, such as the vicinal hydroxyl or amino groups of the oxidisable lipid, to yield aldehyde moieties at the polar head regions of the oxidisable lipids. A 15 sufficient quantity of periodate reagent will usually be a molar ratio with respect to the total of lipid molecules of from about 1.5:1 to about 6:1. The oxidation reaction of the contacting step is typically left to proceed for about one-half hour at room temperature, although the 20 reaction may be permitted to proceed for up to about one hour on ice. The periodate reagent is then preferably removed by gel filtration through a column of dextran polymeric beads having an exclusion limit of about 75,000 daltons.

25 Reaction Schemes I, II and III diagrammatically illustrate the activation of precursor liposomes, with the oxidisable lipids being phosphatidylglycerol, phosphatidylinositol and lactosylceramide respectively.

- 12 -

Reaction Scheme I


- 13 -

Reaction Scheme IIReaction Scheme III

- 14 -

Substantially all of the material which is interior the outer surfaces of the activated liposomes remains encapsulated during the above-described oxidation with periodate reagent. As illustrated by Reaction Schemes I-III, the aldehyde moieties which are formed by the oxidation, or modification, of the oxidisable lipids at the polar head regions thereof define covalent binding sites for the protein to be bound, or coupled.

A wide variety of proteins may be attached, or coupled, to the activated liposomes. The mechanism of coupling is believed to occur between the primary or secondary amino group along the protein and the aldehyde moiety of the activated liposomes so as to form a Schiff-base, for example, with the primary amino group of a lysyl moiety. Such a mechanism is diagrammatically represented by Reaction Scheme IV, which for simplicity illustrates only the terminal galactose (after modification of lactosylceramide).


Reaction Scheme IV

50000

- 15 -

The coupling is driven to completion by a mild reducing agent, preferably sodium cyanoborohydride, so that a stable, covalent bond is formed between the protein and the activated liposome. For example, addition of a sufficient amount of sodium cyanoborohydride drives the Schiff-base of Reaction Scheme IV, above, to completion, as is generally illustrated by Reaction Scheme V, below.

Reaction Scheme V



Reaction Schemes IV and V, above, diagrammatically illustrate coupling of a protein with lactosylceramide, where the lactosylceramide has been modified by oxidation to include aldehyde moieties. Use of the other oxidisable lipids proceeds by an analogous manner. In the instance of modified lactosylceramide, the secondary amine moiety which is covalently binding the protein to the activated liposome may further proceed, in the presence of sodium cyanoborohydride, into an even more stable, tertiary

BUREAU
CIT

- 16 -

amine form.

Although sodium cyanoborohydride is the preferred reducing agent for coupling proteins to the activated liposomes, other reducing agents may be utilized, depending upon the particular circumstances. For example, borohydride may be utilized; however, the coupling reaction would usually then be conducted at a relatively alkaline pH, which may tend to denature the protein being coupled.

10 Suitable proteins for adequate coupling will have at least one primary or secondary amino group, and preferably a plurality of primary or secondary groups. Proteins having at least about 20 lysyl moieties per molecule are more preferred. IgG, with about 60 lysyl
15 moieties, has been found to be particularly well coupled; another preferred antibody for coupling with the activated liposome is F[ab']₂.

Four aqueous solutions of liposome, each containing from about 10 to about 40 micromoles of lipid per
20 milliliter, were activated as previously described. The precursor liposomes had been prepared by the REV procedure and had been extruded through a polycarbonate filter to yield liposomes having a diameter of about 0.2 micron. The solutions were buffered at a pH of from about
25 6.0 to about 8.5. A fifth liposome solution, wherein the oxidisable lipid was not oxidized, was prepared as a control. These four activated liposome solutions in accordance with the present invention and the fifth control solution were as illustrated by Table II.

BUREAU
OF PATENTS

- 17 -

TABLE II

Solution No.	Lipid Composition Molar Ratio	Total Lipid	
		(micromole)	Vol.(ml.)
1	PC/Lactosylceramide, 10:1	9.21	2.8
2	PC/Trihexosylceramide, 10:1	16.44	4.5
3	PC/PG, 1:1	9.5	3.1
4	Galactocerebroside/ PC/Cholesterol, 2:4:5	15	0.6
5*	PC/Lactosylceramide, 10:1	7.11	2.8

10 *Control solution, liposomes not activated

The five solutions as in Table II were treated as follows. Five to ten milligrams of IgG in the same buffer as the liposome solutions were added to the respective liposome solutions (the activated liposomes were suspended in the solutions with substantially no clumping). Sufficient sodium cyanoborohydride was added to give a concentration of about 20 millimolar, and the solutions were left for about two to about three hours at room temperature. The liposomes having covalently bound IgG thereon were then purified by conventional methods, such as column gel filtration or centrifugation. The amount of coupling is illustrated by Table III, below (the number of molecules per vesicle was estimated on the assumption that the vesicles were 0.2 micron in diameter, with about 1.8×10^{12} vesicles/micromole lipid).

TABLE III

<u>Liposome Solution</u>	<u>IgG (mg) added</u>	<u>Protein: Lipid Ratio</u>		<u>Molecules IgG/vesicle</u>
		<u>(μg/ mole)</u>	<u>(μg/mg lipid)</u>	
1	20	112	147	251
2	14	57	75	128
3	14	47	62	106
4	10	96	126	216
5*	20	11	14	25

*Control solution, liposomes not activated.

- 19 -

Binding of Protein to Liposomes

IgG coupling to activated liposomes has typically resulted in the binding of from about 50 to about 200 micrograms of IgG per micromole of lipid. Substantially no coupling is observed in control liposomes. Non-specific binding of proteins to activated liposomes was below the limits of the protein assay utilized in determining coupling.

The proteins which may be covalently bound, or coupled, to the activated liposomes retain a significant amount of biological activity. This is illustrated by use of immunopurified rabbit antiluorescein antibody, as follows.

Antiluorescein IgG binds specifically to fluorescein isothiocyanate and carboxyfluorescein. Upon binding to the antibody, the fluorescence of the fluorescein is abolished, and this was used to measure the binding activity of the antibody. Successive additions of antibody to a solution of carboxyfluorescein reduced the fluorescence due to quenching of the fluorophore upon binding to the antibody. The antigen binding capacity of liposome-bound antibody was compared by correlating the percentage reduction in fluorescence for a variety of specified protein concentrations in linear ranges where quenching was proportional to the protein concentration as illustrated by Table IV, below (wherein the original antibody, or control, linear range was from about 78/1 to about 30/4; and coupled antibody-activated liposomes was linear over the entire range illustrated).

BUREAU

- 20 -

TABLE IV
Fluorescent Intensity/Antibody conc. x 10⁸ (umole/ml)

	<u>Original</u> 5 <u>Antibody</u> <u>(Control)</u>	<u>Unbound Activity</u>	<u>Coupled</u> <u>Antibody-</u> <u>Activated</u> <u>Liposome</u>
	78/1	85/1	95/1
	60/2	75/2	90/2
	40/3	62/3	85/3
10	30/4	50/4	78/4
	18/5	40/5	70/5
	12/6	35/6	65/6
	8/7	30/7	60/7
	8/8	20/8	58/8
15		15/9	50/9

As illustrated by Table IV, above, the fluorescent quenching of carboxylfluorescein by the original antibody preparation (control) and the antibody that was recovered from the coupling process may be compared to antibody bound to the activated liposomes. If the activity of the original, control preparation is set at 100%, then the activity of the activated liposome bound antibody is about 33%, and of the recovered antibody is about 70%. Antigen binding capacity is, therefore, only partially inhibited by the inventive coupling process, and the coupled protein displays, or retains, a significant amount of antigen binding capacity.

Hemagglutination

Liposome-protein conjugates in accordance with

BURE.
C.F.

- 21 -

the present invention have the ability to agglutinate erythrocytes. Activated liposomes, prepared as described above, were conjugated with antigen-antibody, and incubated with erythrocytes conjugated with fluorescein-
 5 isothiocyanate. This resulted in the agglutination of the erythrocytes and the hemagglutinating titre (expressed as the minimum concentration observed to cause agglutination) was improved by a factor of about 1.5 with respect to the original, soluble antibody from which the
 10 liposome-protein conjugates were derived. Lower values of the hemagglutinating titre indicate more effective agglutination capacity. This is illustrated by Table V, below.

TABLE V

15 Hemagglutination of FITC-Human Erythrocytes
By Rabbit Antifluorescein IgG

<u>Preparation</u>	<u>Titre (microgram/ml)</u>
Liposomes Bound Antibody (500 molecules/vesicle)	1.22
20 Untreated Antibody	1.92

The improved ability of liposome-protein conjugates in accordance with the present invention to agglutinate erythrocytes is also demonstrated in another preparation of liposome-protein conjugates via the acti-
 25 vated liposome precursor, as follows.

10 mg of F[ab']₂ was added to 10 μmole of vesicle lipid (after oxidation and desalting) to 1 ml of borateasline (pH 8.4), and then added 10 μl of 1M sodium

BUREAU
C-81

- 22 -

cyanoborohydride. After 18 hours at room temperature, the vesicles were separated from unbound protein by flotation on discontinuous dextran gradients (0 to 20 percent, weight to volume). For quantitation of binding to cells the vesicles contained ^3H -labeled dipalmitoylphosphatidylcholine (DPPC; $10\text{ }\mu\text{Ci}/\mu\text{mole}$) and ^{14}C -labeled sucrose ($1\text{ }\mu\text{Ci}/\mu\text{mole}$). "Targeted" vesicles were those having coupled rabbit $\text{F}[\text{ab}']_2$ to human erythrocytes, whereas "control" vesicles were coupled to $\text{F}[\text{ab}']_2$ prepared from rabbit gamma globulin by pepsin digestion and absorption to a *Staphylococcus aureus* suspension.

The targeted vesicles and the control vesicles were then separately incubated with 10^6 to 10^8 human erythrocytes in 0.2 ml of phosphate-buffered saline (PBS) at pH 7.4 for 1 hour at 37°C . Cells were washed to remove unbound vesicles and were either taken up directly in 10 ml of Triton-toluene scintillant and counted for $[\text{H}]^3\text{DPPC}$ (10^6 to 10^7 cells) or extracted after washing 10^8 cells; the chloroform phase was evaporated and counted for $[\text{H}]^3\text{DPPC}$ content, and the aqueous phase was incubated overnight at 60°C to remove methanol and counted for $[\text{C}]^{14}$ sucrose content.

When vesicles (with from about 1 to 500 nmole of lipid) were incubated with 10^8 cells there was a marked difference between targeted and control binding, with 80% of the vesicles binding at about 20 to 500 μmole of lipid. Control binding with vesicles conjugated to nonspecific $\text{F}[\text{ab}']_2$ was very low (<1 percent) and did not appreciably increase between 100 and 500 nmole of lipid. Both the vesicle lipids and the encapsulated sucrose bound to the cells in nearly identical proportions, indicating that cell binding caused no loss of vesicle contents and that

BURE.
C-17

- 23 -

the antibody-conjugated liposome preparation was reasonably homogeneous with respect to lipid, encapsulated aqueous marker, and antibody. When vesicles were incubated with 10^7 erythrocytes there was a marked difference in binding between the targeted and non-targeted samples. Although a small fraction of the total available vesicles became bound, the number of vesicles that bound to each cell was increased. Vesicles incubated with 10^6 cells also exhibited binding specificity (not shown), with 6 nmole of specific antibody-bearing vesicles and 2 nmole of nonspecific vesicles being bound when 100 nmole of lipid was incubated with the cells. The addition of serum (25 percent fetal calf) during incubation had no substantial effect on the binding.

The vesicle preparations contained 143 molecules per vesicle, assuming $F[ab']_2$ has a molecular weight of 90,000 and that the vesicle preparations contained 1.8×10^{12} vesicles per micromole (for unilamellar vesicles of 0.2 μm diameter). Antibodies not purified immunologically, such as those used here, may contain only 1 to 5 percent of molecules that are specifically reactive to the cell antigens. The preparation therefore probably contained approximately one to five specific molecules per vesicle, so that most vesicles were specific for the target cells. The use of nonimmunopurified antibodies with coupling method that bind only a few antibody molecules per vesicle would result in many vesicles having no specificity for the target.

The association of 400 nmole of lipid with 10^8 human erythrocytes constitutes a lipid mass three times greater than the lipid content of the cell membranes. If one assumes that the vesicles are 0.2 μm in diameter and

- 24 -

are unilamellar, the number of vesicles bound per cell is 8000 and their encapsulated volume is 0.33 of the cell volume. Thus, about 80% of the targeted vesicles associated with the human erythrocytes.

5 The hemagglutinating titre of the $F[ab']_2$ bound to vesicles was measured and compared to the original antibody preparation. The nonspecific soluble $F[ab']_2$ and the control vesicles derived from it produced no hemagglutination at concentrations up to 1 mg of $F[ab']_2$ per milliliter. The soluble antibody to human erythro-
10 cyte $F[ab']_2$ had a hemagglutination titre of 4 $\mu\text{g/ml}$, and the titre of the liposome-protein conjugates derived from the original, soluble antibody was 1.5 $\mu\text{g/ml}$, for an improvement factor of about 2.7.

15 The extent of improvement, or enhancement, of hemagglutinating activity for suitable liposome-protein conjugates is greater than appears from the data, for example in Table V, since during conjugation some of the bound antibody is partially inactivated. In a further
20 experiment, performed with antifuorescein conjugated liposomes prepared via the activated method, a variety of antibody preparations were obtained by mixing the immunopurified antifuorescein with normal rabbit IgG to vary the extent of antifuorescein substitution. The acti-
25 vity of the antifuorescein was calculated by fluorescence quenching, as previously described and illustrated by Table IV, and this value was used to calculate the number of active antibody molecules per liposome of the liposome-antibody conjugates and the
30 corrected minimum hemagglutinating concentration. The liposome-protein conjugates were contacted with unagglutinated erythrocytes which had been coated with fluorescein. (The uncorrected minimum hemagglutinating

BUREAU

- 25 -

concentration (MHC) is calculated from the total protein concentration.) The data is illustrated by Table VI, below.

TABLE VI

5	Active antibody molecules/liposomes	MHC	corrected MHC	Improvement
		($\mu\text{g/ml}$)	($\mu\text{g/ml}$)	Factor
	67	5.10	1.63	2.3
	100	1.60	0.70	5.6
	186	0.57	0.31	12.6
10	soluble antibody	3.90	3.90	---

The improvement factor, illustrated by Table VI, above, compares the corrected MHC of liposome-protein conjugates to the MHC of the original, soluble antibody from which the liposome-protein conjugates were derived. As may be
 15 seen, the improvement factor varied from about 2.3 to about 12.6, depending upon the number of active antibody molecules which were covalently bound per liposome.

In another preparation of liposome-protein conjugates the liposome-protein conjugates had 50 μg of
 20 antihuman erythrocyte Fab' fragments per μmole liposomal phospholipid (about 500 antihuman Fab' fragments per liposome). The precursor liposomes were formed from PC:cholesterol:PDP-PE and conjugated to Fab' by the procedure of Martin and Papahadjopoulos, J. Biol. Chem.,
 25 (1981-In Press). The minimum hemagglutinating concentration (MHC) for soluble antibody was 5.2 $\mu\text{g/ml}$, whereas the MHC for liposome-protein conjugates was 0.17 $\mu\text{g/ml}$. That is, the agglutination improvement factor was about 30.

BUREAU
CMFI

- 26 -

Binding Inhibition

Another batch of liposome-protein conjugates via activated liposome precursors was prepared and tested with soluble antibody for binding inhibition as follows.

5 The precursor liposomes were prepared from a mixture of phosphatidylcholine:cholesterol:oxidized ganglioside (5:5:1) which contained trace amounts of ^3H dipalmitoylphosphatidylcholine to give 2000 counts per minute (cpm) per nanomole lipid. These vesicles were
10 then conjugated to monoclonal mouse anti H2K^k antibody by reductive amination with sodium cyanoborohydride. The resultant liposome-protein conjugates had an anti-body:lipid ratio of 60 μmole .

Meanwhile, 5×10^6 L929 fibroblasts in con-
15 fluent monolayers in 6 cm petri dishes were incubated for 30 minutes at 37°C with 0.2 ml phosphate buffered solution (PBS) containing 50% serum and 20 nmole lipid to which was conjugated 1.2 μg antibody. The incubation mixture also contained variable amounts of soluble antibody, as
20 indicated in Table VII, below. After incubation, the cells were washed four times with phosphate buffered saline, trypsinized to remove them from the monolayer and taken up in scintillant for counting.

In a similar manner, 2×10^6 R1.1 T-lymphoma
25 cells were suspended in 0.2 ml PBS containing 50% serum, 20 nmole lipid conjugated to 1 μg antibody and various amounts of soluble antibody as indicated in Table VII, below. After 30 minutes they were washed four times by centrifugation and resuspension of the cells in 5 ml
30 portions of PBS. The cells were finally resuspended in 0.5 ml and taken up in scintillant.

The antibody-anti H2K^k reaction which occurred between the liposome-conjugates and the cells (and, to a

BURE.

- 27 -

lesser extent between the soluble antibody and the cells) illustrates a reaction with the H2K of certain mouse strains. This protein is a membrane antigen present at high levels in most mouse tissues. The L929 fibroblast and the R1.1 T-lymphoma are cultured cell lines derived from mice which express the H2K^k antigen.

TABLE VII

INHIBITION OF TARGETED LIPOSOME BINDING
BY SOLUBLE ANTIBODY

Soluble Antibody Per Sample (ug)	Percent Control Binding	
	L929	R1.1
0.1	100%	100%
0.3	86%	97%
1	97%	81%
3	100%	62%
10	95%	44%
30	66%	31%

For example, as illustrated by Table VII above, a ratio of soluble to liposome-bound antibody of at least 10:1 was required to achieve about 50% binding inhibition with the R1.1 T-lymphoma cells. These data demonstrate that liposome-protein conjugates in accordance with the present invention bind with greater functional affinity to their immunological partners than does soluble antibody. It is believed this, and the improved agglutination property, is due to a multivalent character of the liposome-protein conjugates, e.g. that each vesicle contains many antigen binding sites. By contrast, for example, native IgG is only bivalent.

BUREAU

- 28 -

A wide variety of proteins, particularly antibodies, may be covalently bound to liposomes and used in accordance with the present invention. Table VIII, below, illustrates a number of liposome-protein conjugates suitable for immunodiagnostic applications, and particularly for cell agglutinations mediated by combinations with the appropriate antigenic partner.

TABLE VIII

Liposome-Protein Conjugate	Composition #	Bound Antibody	Antibody to Lipid Ratio
			($\mu\text{g}/\mu\text{mole}$)
10	1	Normal bovine IgG	100-300
	2	Normal rabbit IgG	60-300
	3	Normal rabbit F[ab'] ₂	70
15	4	Rab. antiHRBC F[ab'] ₂	60
	5	Mouse IgG	98
	6	Rabbit anti CVI	107
20	7	Normal rabbit IgG	275
	8	anti sheep RBC (2a)*	153
	9	anti H2K _k (2a)*	72
	10	anti Thy 1.1 (1)*	50
	11	anti sheep RBC (2a)*	121
	12	anti H2K _k (2a)*	70
25	13	Normal human IgG	235
	14	anti H2K _k (2)*	52
	15	Mouse IgG (All)*	128
	16	anti glycophorin (1)*	240
	17	anti sheep RBC (2a)*	000
30	(*wherein the symbol within the parentheses gives the IgG subclass of the antibody)		

BUREAU
C-11

- 29 -

Composition numbers 1-10, above, were prepared from precursor liposomes by the activated liposome method (e.g., glycosphingolipids were oxidized with periodate and antibody was covalently bound by reductive amination with sodium cyanoborohydride). The lipid of compositions 1 and 2 were lactosylceramide, phosphatidylglycerol, phosphatidylcholine and cholesterol in a ratio of 10:3:45:45. The lipid of compositions 3-10 consisted of phosphatidylcholine, cholesterol and ganglioside in a ratio of 5:5:1. The antibody of compositions 8-10 was monoclonal (mouse).

Compositions 11 and 12 were prepared from precursor liposomes by a preoxidation modification of the activated liposomes method (e.g. gangliosides were preoxidized, the precursor liposomes were formed therefrom, and the antibody then conjugated as in the activated liposome method). More particularly, gangliosides, usually a mixture from bovine brain, are suspended in 20 mM and sodium-in-periodate at pH 5.5. After 30 minutes at room temperature in the dark, ethylene glycol is added to a final conc of 100 mM and the solution is left 30 minutes. Oxidized gangliosides are separated from the reaction products by gel chromatography. The ganglioside fractions are pooled, mixed with methanol and evaporated to dryness under a stream of nitrogen. The residue is taken up in chloroform:methanol (1:1) and stored under argon at -40°C before protein conjugation. Lipid content was as described for compositions 3-10, above. The antibody was monoclonal (mouse).

Compositions 13-17 were prepared as follows.

N-[4-(p-maleimidophenyl)butyryl]phosphatidylethanolamine (MPB-PE) was synthesized by the procedure of Martin and

BUREAU

- 30 -

Papahadjopoulos, J. Biol. Chem. (1981-In Press). Liposomes are then prepared by the method of Szoka and Papahadjopoulos, supra, from 10:10:1 phosphatidylcholine:cholesterol:MPB-PE in a buffer at pH 6.0-6.7. A
5 suitable buffer is 0.05 M morpholino-ethanesulfonic acid, 0.096 M NaCl, pH 6.4. It is essential to prepare the vesicle below pH 7.0 to ensure the maximal stability of the maleimide function. The antibody is pyridylthiolated and reduced by the method of Carlsson et
10 al. Biochem.J., 173, pp. 723-737 (1978). Reaction of protein with 10 mole of N-Succinimidyl 3-(2-Pyridyldithiol) Propionate (SPDP) per mole of protein results in the substitution of 3-5 mole of pyridyldithiol groups per mole protein. After reduction with dithio-
15 threitol, the protein is separated from the reducing agent on a polyacrylamide column (50 to 100 mesh) equilibrated in argon-purged (de-oxygenated) buffer, pH 6.0-6.5. The protein fractions are pooled and concentrated to a suitable volume under argon in an amicon type
20 concentrator. Commonly, the protein is concentrated to around 3 mg/ μ l. Liposomes are then added to the protein solution with stirring to give 5 μ mole lipid per ml. After reaction overnight, the vesicles are reacted with Aldrithiol 4 and separated on a metrizamide gradient and
25 the protein and lipid are determined. The protein, or antibody, was modified in compositions 13-17 by from about 1.8 to about 5.1 thiols per molecule.

Industrial Applicability

The enhanced agglutination activity of lipo-
30 some-protein conjugates is useful for a variety of diagnostic applications, such as in inhibition assays and flocculation tests. Hemagglutinin inhibition assays

BUREAU
- CMT

- 31 -

measure the extent to which a soluble antigen inhibits the capacity of its specific antibody to agglutinate antigen-sensitized erythrocytes. Liposome-protein conjugates can increase the sensitivity of hemagglutination inhibition assays. Since considerably less antibody is required for agglutination, a correspondingly less amount of soluble antigen will inhibit agglutination. That is, soluble antigen will compete with an erythrocyte surface antigen of the same antigenic specificity, and thus the presence of soluble antigen will reduce the amount of agglutination produced by liposome-protein conjugates specific for the antigen. One may thus determine the extent to which the soluble antigen inhibits cell agglutination mediated by antibody-antigen interaction. Among the human serum antigens which may be detected by the more sensitive liposome-protein conjugates are peptide hormones, such as thyroxin, C-reactive protein, hepatitis surface antigen, hCG, heterophile antibodies, rheumatoid antibodies, thyroxin binding protein (T_3) and digoxin.

In addition, liposome-protein conjugates may be used in flocculation tests. For example, where the liposome-protein conjugates have an antibody covalently bound to the liposomes, the antibody may be selected with an antigen binding capacity for a particle such as the Dane particle of hepatitis B virus, which would be more sensitively flocculated, or agglutinated, when contacted with the liposome-protein conjugates than when conjugates are derived.

The best mode contemplated for carrying out the present invention is use of liposome-protein conjugates in blood typing. The preferred size of liposomes for such use is from about 0.1 micron to about 5 micron, and

BUREAU

- 32 -

more preferred from about 0.1 to about 0.5 micron.

The size is most preferably controlled by extrusion through straight pore polycarbonate filters, as is described in U.S. Patent 4,263,428, issued April 21, 1981. The extrusion permits the production of uniform vesicles in selected sizes between about 0.1 and about 0.5 micron.

The antibody preparation is covalently bound to the liposome so that the antibody is in an amount of at least about 40 micrograms per micromole of lipid molecules, more preferably from about 40 to about 90 micrograms per micromole of lipid. The antibody may be derived from a normal polyclonal antiserum, or from a monoclonal antibody. The liposome-protein conjugates are then separated from the soluble, unbound antibody by flotation in a discontinuous metrizamide gradient. The recovered liposome-protein conjugates may then be analyzed for protein and lipid content.

To establish the minimum quantity of the liposome-protein conjugates required for agglutination, serial two-fold dilutions of the liposome-protein conjugates are prepared in a hemagglutination plate (e.g. one-half, one-quarter, one-eighth, one-sixteenth, etc.). These dilutions are then mixed with an equal volume of a 2% erythrocyte suspension and left to stand for about 18 hours. The wells are then scored for agglutination, and the most dilute solution which gives agglutination is taken to be the minimum hemagglutination concentration.

BULL.
C-77

- 33 -

Liposome-protein conjugates at a concentration known to give agglutination of antigen-positive cells are then mixed with erythrocytes whose expression of the antigen is to be determined. After incubation for a
5 suitable period, the cells are scored for agglutination.

While the invention has been described in connection with specific embodiments thereof, it will be understood that it is capable of further modification, and this application is intended to cover any variations,
10 uses or adaptations of the invention following in general, the principles of the invention and including such departures from the present disclosures as come within known or customary practice in the art to which the invention pertains and as may be applied to the essential
15 features hereinabove set forth, and as fall within the scope of the invention and the limits of the appended claims.

BUREAU
OF PATENTS

- 34 -

Claims

1. A diagnostic method comprising:
providing liposome-ligand conjugates, the
liposome-ligand conjugates including liposomes and
ligand, the liposomes having lipid molecules, the ligand
5 being covalently bound to the liposomes and in an amount
of at least 40 micrograms per micromole of lipid
molecules;
contacting the liposome-ligand conjugates with
ligand-binding molecules to form a mixture, the ligand-
10 binding molecules carried by at least one surface; and,
examining the mixture for interactions between
the ligand of the liposome-ligand conjugates and the
ligand-binding molecules.
2. The diagnostic method of claim 1 wherein:
15 the at least one surface is a plurality of
surfaces defined by discrete particles.
3. The diagnostic method of claim 1 wherein:
the ligand-binding molecules are carried by
cells along surfaces thereof.
- 20 4. The diagnostic method of claim 2 or 3
wherein:
the ligand of the liposome-ligand conjugates is
an antibody having an antigen binding capacity, and the
ligand-binding molecules are antigens.
- 25 5. The diagnostic method of claim 4 wherein:
the examining includes determining cell agglu-
tination mediated by antibody-antigen interaction.

BUREAU
C/T

- 35 -

6. The diagnostic method of claim 4 wherein:
the examining includes determining particle
agglutination mediated by antibody-antigen interaction.

7. An agglutination method useful for assay-
5 ing cell surface antigens comprising:

providing liposome-protein conjugates, the
liposome-protein conjugates including liposomes and
protein, the liposomes having lipid molecules, the
protein supplying an antigen binding capacity for at
10 least a majority of the liposome-protein conjugates, the
protein in an amount of at least about 40 micrograms per
micromole of lipid molecules;

contacting the liposome-protein conjugates
with substantially unagglutinated cells to form a mix-
15 ture; and,

examining the mixture for cell agglutination.

8. The agglutination method of claim 7 where-
in:

the cells of the contacting and examining steps
20 are erythrocytes, lymphocytes or leukocytes.

9. The agglutination method of claim 8 where-
in:

the cells of the contacting and examining steps
are erythrocytes.

- 36 -

10. The agglutination method of claim 9 wherein:

the protein includes IgG or a fragment thereof, and the antigen binding capacity is for erythrocytes bearing a surface antigen for which the IgG or fragment thereof is specific.

11. The agglutination method of claim 7 or 10 wherein:

the examining includes determining cell agglutination mediated by antibody-antigen interaction.

12. A reagent, useful for hemagglutination assays, comprising:

liposome-protein conjugates, the liposome-protein conjugates including liposomes and antibody covalently bound to the liposomes, the liposomes having lipid molecules, the antibody having an antigen binding capacity for erythrocytes bearing a surface antigen for which the antibody is specific, the antibody in an amount of at least about 40 micrograms per micromole of lipid molecules, the liposome-protein conjugates having an enhanced hemagglutinating activity with respect to the hemagglutinating activity of antibody from which the liposome-protein conjugates are derived.

13. The reagent of claim 12 wherein:

the antibody is derived from a polyclonal antiserum or is a monoclonal antibody, and the hemagglutinating activity is determinable as a minimum hemagglutinating concentration.

- 37 -

14. The reagent as in claim 12 wherein:
the enhanced hemagglutinating activity is at
least about 1.5 times greater than the hemagglutinating
activity of antibody from which the liposome-protein
5 conjugates are derived.

15. The reagent as in claim 12 wherein:
the liposomes of the liposome-protein conju-
gates are from about 0.1 micron to about 5 micron in size.

16. The reagent as in claim 12 wherein:
10 the liposomes are a substantially uniform size
between about 0.1 and about 0.5 microns.


17. The reagent as in claim 15 or 16 wherein:
the antibody is IgG or a fragment thereof.

18. The reagent as in claim 17 wherein:
15 the IgG or fragment thereof is in an amount of
from about 40 micrograms to about 90 micrograms per
micromole of lipid molecule.

BUREAU

INTERNATIONAL SEARCH REPORT

International Application No. PCT/US82/01524

I. CLASSIFICATION OF SUBJECT MATTER (If several classification symbols apply, indicate all) ¹ According to International Patent Classification (IPC) or to both National Classification and IPC Int. Cl. ³ A61K 39/44; B01J 13/02; C07G 7/00; G01N 33/48, 33/54, 33/80; U.S. Cl. 252/316; 260/112R, 112B; 424/11, 38, 85, 88; 436/518, 519, 520, 521, 547, 548, 829						
II. FIELDS SEARCHED <div style="text-align: center; border-top: 1px solid black; border-bottom: 1px solid black; margin: 5px 0;">Minimum Documentation Searched ⁴</div> <table style="width: 100%; border-collapse: collapse;"> <tr> <th style="width: 25%; border-bottom: 1px solid black;">Classification System</th> <th style="border-bottom: 1px solid black;">Classification Symbols</th> </tr> <tr> <td style="border-right: 1px solid black; padding: 5px;">U.S.</td> <td style="padding: 5px;">260/112R, 112B; 252/316; 424/11, 38, 85, 88; 436/518, 519, 520, 521, 547, 548, 829</td> </tr> </table> <div style="text-align: center; border-top: 1px solid black; border-bottom: 1px solid black; margin: 5px 0;">Documentation Searched other than Minimum Documentation to the Extent that such Documents are Included in the Fields Searched ⁵</div>			Classification System	Classification Symbols	U.S.	260/112R, 112B; 252/316; 424/11, 38, 85, 88; 436/518, 519, 520, 521, 547, 548, 829
Classification System	Classification Symbols					
U.S.	260/112R, 112B; 252/316; 424/11, 38, 85, 88; 436/518, 519, 520, 521, 547, 548, 829					
III. DOCUMENTS CONSIDERED TO BE RELEVANT ¹⁴						
Category ⁶	Citation of Document, ¹⁵ with indication, where appropriate, of the relevant passages ¹⁷	Relevant to Claim No. ¹⁸				
AX	US, A, 4,232,001, published 4 November 1980, Jensen	1-18				
AX	US, A, 4,193,983, published 18 March 1980, Ullman	1-18				
AX	US, A, 3,887,698, published 3 June 1975, McConnell	1-18				
AX	N, Biochemical and Biophysical Research Communications, Vol. 85, issued 14 December 1978 (New York, N.Y., USA) V.P. Torchilin, Comparative Studies on Covalent and Non-covalent Immobilization of Protein Molecules on the Surface of Liposomes, pp. 983-990	1-18				
AX	N, Biochemical and Biophysical Research Communications, Vol. 89, issues 28 August 1979 (New York, N.Y., USA) V.P. Torchilin, Preservation of an Antimyosin Antibody Activity After Covalent Coupling to Liposomes, pp. 1114-1119	1-18				
CONTINUED ON SUPPLEMENTAL SHEETS						
<div style="display: flex; justify-content: space-between;"> <div style="width: 45%;"> <p>¹⁶ Special categories of cited documents:</p> <p>"A" document defining the general state of the art</p> <p>"E" earlier document but published on or after the international filing date</p> <p>"L" document cited for special reason other than those referred to in the other categories</p> <p>"O" document referring to an oral disclosure, use, exhibition or other means</p> </div> <div style="width: 45%;"> <p>"P" document published prior to the international filing date but on or after the priority date claimed</p> <p>"T" later document published on or after the international filing date or priority date and not in conflict with the application, but cited to understand the principle or theory underlying the invention</p> <p>"X" document of particular relevance</p> </div> </div>						
IV. CERTIFICATION						
Date of the Actual Completion of the International Search ¹⁹ <div style="text-align: center; font-weight: bold;">17 FEB 1982</div>	Date of Mailing of this International Search Report ²⁰ <div style="text-align: center; font-weight: bold;">18 FEB 1983</div>					
International Searching Authority ¹ <div style="text-align: center; font-weight: bold;">ISA/US</div>	Signature of Authorized Officer ²⁰ <div style="text-align: center;">  </div>					

III. DOCUMENTS CONSIDERED TO BE RELEVANT (CONTINUED FROM THE SECOND SHEET)		
Category *	Citation of Document, ¹⁶ with indication, where appropriate, of the relevant passages ¹⁷	Relevant to Claim No ¹⁸
AX	N, Biochemical and Biophysical Research Communications, Vol. 90, issued 27 September 1979 (New York, N.Y., USA) D. Sinha, Attachment to Membranes of Exogenous Immunoglobulin Conjugated to a Hydrophobic Anchor, pp. 554-560	1-18
A	N, FEBS Letters, Vol. 111, issued 25 February 1980 (Amsterdam, The Netherlands) V.P. Torchilin, Coating Liposomes with Protein Decreases Their Capture by Macrophages, pp. 184-188	1-18
A	N, Biochemica et Biophysica Acta, Vol. 602, issued 18 November 1980 (Amsterdam, The Netherlands) V.P. Torchilin, Incorporation of Hydrophilic Protein Modified with Hydrophobic Agent Into Liposome Membrane, pp. 511-521	1-18
AX	N, Science, Vol. 210, reprint series, issued 31 October 1980 (Washington, D.C., USA) T.D. Heath, Antibody Targeting of Liposomes: Cell Specificity Obtained by Conjugation of F(ab') ₂ to Vesicle Surface, pp. 539-541	1-18
AX	N, Nature, Vol. 288, issued 11 December 1980 (London, England) L.D. Leserman, Targeting to Cells of Fluorescent Liposomes Covalently Coupled with Monoclonal Antibody or Protein A, pp. 602-604	1-18
AX	N, The Journal of Biological Chemistry, Vol. 255, issued 10 September 1980 (Baltimore, MD., USA) A. Huang, Monoclonal Antibody Covalently Coupled with Fatty Acid, pp. 8015-8018	13
AX	N, Biochimica et Biophysica Acta, Vol. 640, issued 8 January 1981 (Amsterdam, The Netherlands) T.D. Heath, Covalent Attachment of Immunoglobulins to Liposomes via Glycosphingolipids, pp. 66-81	1-18
AX	N, Biochemistry, Vol. 20, issued 7 July 1981 (Easton, PA., USA) F.J. Martin, Immuno-specific Targeting of Liposomes to Cells: A Novel and Efficient Method for Covalent Attachment of Fab' Fragments via Disulfide Bonds, pp. 4229-4238	1-18
AX	N, Federation Proceedings, Vol. 38, No. 3, issued 1 March 1979 (Bethesda, MD., USA) D. Sinha, The Attachment to Membranes of	1-18

III. DOCUMENTS CONSIDERED TO BE RELEVANT (CONTINUED FROM THE SECOND SHEET)		
Category*	Citation of Document, ¹⁶ with indication, where appropriate, of the relevant passages ¹⁷	Relevant to Claim No. ¹⁸
	(CONTINUED)	
	Exogenous Immunoglobulin Conjugated to a Hydrophobic Anchor, page 942, Abstract No. 3766	
AX	N, Federation Proceedings, Vol. 39, No. 6, issued 1 May 1980 (Bethesda, MD., USA) D. Sinha, Conjugation of a Hydrophobic Anchor to Rabbit Fab' and its Attachment to Liposomal Membranes, page 1761, Abstract No. 825	1-18

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ **BLACK BORDERS**
- ☐ **IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- ☐ **FADED TEXT OR DRAWING**
- ☐ **BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- ☐ **SKEWED/SLANTED IMAGES**
- ☐ **COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- ☐ **GRAY SCALE DOCUMENTS**
- ☐ **LINES OR MARKS ON ORIGINAL DOCUMENT**
- ☒ **REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- ☐ **OTHER:** _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.